Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I

Journal of Clinical Pharmacology

Volumn 36, Issue 2, 1996, Pages 117-121

  Viliani, Paola ^a   Maserati, Renato ^a   Regazzi, Mario B ^a   Giacchino, Roberto ^a   Lori, Franco ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HYDROXYUREA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MIXTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION;

EID: 0029923839     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04176.x     Document Type: Article

References (13)

1. Yarbro JW: Mechanism of action of hydroxyurea. Semin Oncol 1992; 19(suppl 9):1-10.
2. Donehower RC: An overview of the clinical experience with hydroxyurea. Semin Oncol 1992; 19:11-19.
3. Cortellazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al: Hydroxyurea for patients with essential thrombocytemia and high risk of thrombosis. New Engl J Med 1995; 332: 1132-1136.
4. Charache S, Terrin MI, Moore RD, Dover GJ, Barton FB, Eckert SV, et al: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. New Engl J Med 1995; 332:1317-1322.
5. Stehman FB: Experience with hydroxyurea as a radiosensitizer in carcinoma of the cervix. Semin Oncol 1992; 19(suppl 9):48-52.
6. Gao WY, Cara A, Gallo RC, Lori F: Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A 1993; 90:892-898.
7. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994; 266:801-805.
8. Malley SD, Grange JM, Hamedi SF, Vila JR: Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds (letter). Lancet 1994; 343:1292.
9. Havard J, Grygiel J, Sampson D: Determination by high-performance liquid chromatography of hydroxyurea in human plasma. J Chromatogr 1992; 584:270-274.
10. Gao WY, Johns DG, Mitsuya H: Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994; 46:767-772.
11. Belt RJ, Haas CD, Kennedy J, Taylor S: Studies of hydroxyurea administered by continuous infusion. Cancer 1980; 46:455-462.
12. Tracewell WG, Trump DL, Vaughan WP, Smith DC, Gwilt PR: Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother Pharmacol 1995; 35:417-422.
13. Rosner F, Rubin H, Parise F: Studies on the absorption, distribution and excretion of hydroxyurea [NSC-32065). Cancer Chemother Rep 1971:55:167-173.